Onconox Inc. Appoints Geoff Muckle as Chief Executive Officer to Lead Clinical Advancement and Strategic Growth

Summary

Onconox Inc. has appointed biotech executive Geoff Muckle as CEO to strengthen the company’s leadership and drive OCN001 toward first-in-human studies in 2026. Geoff brings more than two decades of oncology and biotech experience spanning Roche, Champions Oncology, and Link Medical Solutions, and will lead the company’s evolution from a single-asset entity to a scalable platform-driven biotech.

Onconox Inc., a biotechnology company developing precision, low-burden therapies for patients with lung cancer and other high-need indications, today announced the appointment of Geoff Muckle as Chief Executive Officer. Geoff assumes leadership at a pivotal stage for the company as it prepares its lead program, OCN001, for clinical entry in 2026 and advances its broader innovation strategy.

A seasoned biotech executive, Geoff Muckle brings over twenty years of experience spanning oncology therapeutics, diagnostics, and pharmaceutical innovation. His career includes senior leadership positions at Roche, Champions Oncology, and Link Medical Solutions, where he has led multiple organizations through clinical translation, strategic repositioning, capital formation, and commercial expansion across international markets.

As CEO of Onconox, Geoff is steering the company’s transformation from a single-asset focus to a scalable platform biotech. Under his leadership, Onconox is advancing a pipeline of precision therapies delivered via inhaled and intranasal routes, designed to reduce treatment burden, improve tolerability, and accelerate development timelines through pragmatic regulatory pathways.

Commenting on the appointment, Dr Sitaram Velaga, Founder and President of Onconox Inc., said:"Geoff’s track record in building, scaling, and financing oncology ventures makes him the ideal leader for Onconox at this stage of development. His strategic insight and operational discipline will be instrumental as we transition OCN001 into the clinic and expand the company’s platform capabilities."

Geoff Muckle added:"Onconox has already laid a strong scientific and regulatory foundation for OCN001, and I am excited to lead the company into its next phase. Our goal is to bring precise, well-tolerated therapies to patients faster, beginning with our first-in-class inhaled program in lung cancer and expanding into a broader pipeline with significant long-term potential."

Geoff’s appointment marks a significant milestone in strengthening the company’s leadership and preparing for the operational, financial, and clinical execution required to deliver a successful IND submission and first-in-human study in 2026.

Further updates on Onconox’s development roadmap and strategic initiatives will be shared throughout 2025.